AlloVir to Merge with Kalaris Therapeutics, Pioneers in Retinal Disease Treatment

AlloVir, a notable player in the biopharmaceutical sector, has announced a definitive merger agreement with Kalaris Therapeutics, another clinical-stage biopharmaceutical company, focusing on retinal diseases. This strategic merger will result in the creation of an entity centered on innovating treatments for retinal disorders, particularly targeting the significant $14 billion anti-VEGF market. Kalaris Therapeutics, backed by Samsara BioCapital, is pioneering a promising anti-VEGF therapy, TH103, developed by Dr. Napoleone Ferrara. This therapy holds potential beyond current treatments in extending injection intervals and improving compliance in treating neovascular age-related macular degeneration (nAMD) and other diseases. The merger promises AlloVir’s financial robustness to accelerate the clinical development of this ground-breaking therapy. Once finalized, the merger will result in Kalaris managing the combined entity with AlloVir's Chairman, David Hallal, continuing in his role within the board. The combined company anticipates a stronger cash position, projected to sustain operations into late 2026, with the first financial closure scheduled for Q1 2025. Strategic advisors such as Leerink Partners and Goodwin Procter LLP will facilitate the transaction expected to finalize in early 2025, subject to regulatory approvals.